文献速递重症综合管理与镇静镇痛

苯磺酸瑞马唑仑与丙泊酚用于重症患者深度镇静:一项随机预试验

Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study.
PubMed 文献 · Crit Care · 2023-12-04
一句话结论单中心随机预试验显示,苯磺酸瑞马唑仑用于重症患者短期深度镇静似乎有效且安全,但样本量小,需大样本随机临床试验。

该单中心、前瞻性、随机对照预试验将60例需要深度镇静(RASS -4或-5)的ICU患者随机分为苯磺酸瑞马唑仑组和丙泊酚组,每组30例。主要终点为无补救镇静下目标镇静范围内时间百分比,两组中位RASS达标时间均为镇静时间的100%。7天内无呼吸机时长、成功拔管、ICU住院时间和28天死亡率组间无显著差异;低血压发生率瑞马唑仑组16例(53.3%)vs 丙泊酚组18例(60.0%)(p>0.05),无患者发生心动过缓。作者认为苯磺酸瑞马唑仑似乎是重症患者短期深度镇静的有效且安全药物,但需大样本随机临床试验验证。

要点

  • 两组中位RASS达标时间均为镇静时间的100%,提示苯磺酸瑞马唑仑与丙泊酚均能达到深度镇静目标。
  • 低血压发生率:瑞马唑仑组16例(53.3%)vs 丙泊酚组18例(60.0%),p>0.05,无统计学差异。
  • 无患者发生心动过缓。
  • 7天内无呼吸机时长、成功拔管、ICU住院时间和28天死亡率组间无显著差异。
  • 作者认为苯磺酸瑞马唑仑似乎是重症患者短期深度镇静的有效且安全药物,但需大样本随机临床试验。

适用人群与场景

  • ICU需要深度镇静(RASS -4或-5)的危重患者。

诊断标准与关键阈值

  • 深度镇静定义为Richmond躁动-镇静评分(RASS)-4或-5分。
  • 镇静深度通过RASS和Narcotrend指数(NI)监测。

研究设计与关键结果

  • 单中心、前瞻性、随机对照预试验,每组30例,比较苯磺酸瑞马唑仑与丙泊酚静脉给药用于ICU深度镇静。
  • 干预期间中位(IQR)RASS评分为-5.0(-5.0,-4.0),中位(IQR)NI值为29.0(21.0,37.0)。
  • 主要终点:两组目标RASS达标时间中位数均为镇静时间的100%。
  • 次要终点:7天内无呼吸机时长、成功拔管、ICU住院时间和28天死亡率组间无显著差异。
  • 低血压:瑞马唑仑组16例(53.3%)vs 丙泊酚组18例(60.0%),p>0.05。
  • 无患者发生心动过缓。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性、随机对照预试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为苯磺酸瑞马唑仑似乎是重症患者短期深度镇静的有效且安全药物。
  • 作者指出本研究结果需大样本随机临床试验验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the efficacy and safety of remimazolam besylate and propofol for deep sedation in critically ill patients.

METHODS: In this single-center, prospective, randomized, controlled pilot study, patients in the intensive care unit (ICU) requiring deep sedation were randomized to receive remimazolam besylate or propofol intravenously. Deep sedation was defined as a Richmond Agitation and Sedation Scale (RASS) score of - 4 or - 5. Sedation depth was monitored using RASS and Narcotrend Index (NI). The primary outcome was the percentage of time within the target sedation range without rescue sedation. The secondary outcomes included ventilator-free hours within 7 days, successful extubation, length of ICU stay, and 28-day mortality. Adverse events during the interventional period were also recorded.

RESULTS: Thirty patients were assigned to each group. The median (IQR) RASS score was - 5.0 (- 5.0, - 4.0), and the median (IQR) NI value was 29.0 (21.0, 37.0) during the intervention period. Target RASS was reached a median of 100% of the sedation time in the two groups. No significant differences were observed in ventilator-free hours within 7 days, successful extubation, length of ICU stay, or 28-day mortality among groups. Hypotension occurred in 16 (53.3%) patients of remimazolam group and 18 (60.0%) patients of propofol group (p > 0.05). No patient experienced bradycardia.

CONCLUSIONS: Remimazolam besylate appears to be an effective and safe agent for short-term deep sedation in critically ill patients. Our findings warrant large sample-sized randomized clinical trials.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Tang Y, Gao X, Xu J, et al. Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study. Crit Care. 2023. PMID: 38049909. doi:10.1186/s13054-023-04760-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。